Valencia, March 14, 2019 – Celebrating the World Kidney Day, QUIBIM, with the support of the Parenchima initiative, organized the first QUIBIM Precision Training Workshop for leading scientific researchers in medical imaging of kidney from 25 European countries.
On March 12th – 13th, QUIBIM hosted its first face-to-face workshop in Valencia (Spain) to train researchers and engineers who want to integrate medical image quantification algorithms in the Quibim Precision® platform. This is an initiative by QUIBIM with the objective of opening the platform to radiologists, clinicians and researchers who want to develop and implement their own MRI algorithms for chronic kidney disease.
QUIBIM was selected in the previous annual meeting of the Parenchima consortium in Prague, (October 4th-5th, 2018), as the best system for medical imaging data management and integration of new analysis algorithms for the COST action project. Thanks to its ability to centralise, manage and store data extracted from the medical images from the different partner hospitals in a single platform, QUIBIM offers the project to allow for acquisition protocols and algorithms comparison in terms of quality and precision, all at the same place.
The outcome of the project will consist of new standards for image acquisition and analysis of MRI of the kidney for chronic kidney disease. QUIBIM’s team enjoyed hosting the workshop for the partners and are excited to be part of such a groundbreaking initiative.
Renal MRI biomarkers are underused today in research and in clinical practice due to the need for dedicated in-house expertise and development. Transferring solutions to other centres is therefore a challenge, and this leads to a significant duplication of efforts, a lack of standardisation in the methods, and difficulties in comparing results between centres. This also limits commercial exploitation, and hinders the set-up of multi-centre trials or translation into clinical practice.
The overall aim of PARENCHIMA is to eliminate the main barriers to the broader study, commercial exploitation and clinical use of renal MRI biomarkers.
PARENCHIMA will coordinate the research of leading European groups in this area to:
- improve the reproducibility and standardisation of renal MRI biomarkers;
- increase their availability by developing an open-access toolbox with software and data;
- demonstrate biological validity and clinical utility in a prospective multicentre clinical study.
In order to increase the impact of this project we are reaching out to join the efforts. More info at: www.renalmri.org
QUIBIM is a company from Valencia (Spain) which applies artificial intelligence and advanced computational models to radiological images to objectively measure changes produced by a lesion or by a pharmacological treatment, offering additional quantitative information to the qualitative approach of radiology. QUIBIM technology and services are applied in clinical practice, clinical trials, radiology education and research projects. More info at: www.quibim.com